Home › Research › Biomarkers
CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease
Barba L, Abu-Rumeileh S, Halbgebauer S, Bellomo G, Paolini Paoletti F, Gaetani L, Oeckl P, Steinacker P et al.. Neurology, 2023-05-15
Topic: Brain proteins, microglia and lab models
Plain-language summary
Background and objectives Patients with Lewy body disease (LBD) often show a co-occurring Alzheimer disease (AD) pathology. CSF biomarkers allow the detection in vivo of AD-related pathologic hallmarks included in the amyloid-tau-neurodegeneration (AT(N)) classification system. Here, we aimed to investigate whether CSF biomarkers of synaptic and neuroaxonal damage are correlated with the presence of AD copathology in LBD and can be useful to differentiate patients with LBD with different AT(N) profiles. Methods We retrospectively measured CSF levels of AD core biomarkers (Aβ42/40 ratio, phosphorylated tau protein, and total tau protein) and of synaptic (β-synuclein, α-synuclein, synaptosomal-associated protein 25 [SNAP-25], and neurogranin) and neuroaxonal proteins (neurofilament light chain [NfL]) in 28 cognitively unimpaired participants with nondegenerative neurologic conditions and 161 participants with a diagnosis of either LBD or AD (at both mild cognitive impairment, AD-MCI, and dementia stages, AD-dem). We compared CSF biomarker levels in clinical and AT(N)-based subgroups. Results CSF β-synuclein, α-synuclein, SNAP-25, neurogranin, and NfL levels did not differ between LBD (n = 101, age 67.2 ± 7.8 years, 27.7% females) and controls (age 64.8 ± 8.6 years, 39.3% females) and were increased in AD (AD-MCI: n = 30, AD-dem: n = 30, age 72.3 ± 6.0 years, 63.3% females) compared with both groups ( p p p = 0.0021), α-synuclein ( p = 0.0099), and SNAP-25 concentrations ( p = 0.013) were also higher in LBD/A+T+ than in LBD/A+T- cases, which had synaptic biomarker levels within the normal range. CSF α-synuclein was significantly decreased only in patients with LBD with T- profiles compared with controls ( p = 0.0448). Moreover, LBD/A+T+ and AD cases did not differ in any biomarker level. Discussion LBD/A+T+ and AD cases showed significantly increased CSF levels of synaptic and neuroaxonal biomarkers compared with LBD/A-T- and control subjects. Patients with LBD and AT(N)-based AD copathology showed, thus, a distinct signature of synaptic dysfunction from other LBD cases. Classification of evidence This study provides Class II evidence that CSF levels of β-synuclein, α-synuclein, SNAP-25, neurogranin, and NfL are higher in patients with AD than in patients with LBD.
What this study adds
Evidence grade: Low
The record lists 101 participants. In patients with Lewy body disease, several CSF synaptic and neuroaxonal markers did not differ from controls but were increased in Alzheimer's disease, and one marker was decreased only in a specific subgroup. Reported effect size: 27.7%; 39.3%; 63.3%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Barba, L., Abu-Rumeileh, S., Halbgebauer, S., Bellomo, G., Paolini Paoletti, F., Gaetani, L., et al. (2023). CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease. Neurology. https://doi.org/10.1212/wnl.0000000000207371
Vancouver
Barba L, Abu-Rumeileh S, Halbgebauer S, Bellomo G, Paolini Paoletti F, Gaetani L, et al. CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease. Neurology. 2023. doi:10.1212/wnl.0000000000207371. PMID: 37188538.
BibTeX
@article{barba2023-37188538,
author = {Barba, L. and Abu-Rumeileh, S. and Halbgebauer, S. and Bellomo, G. and Paolini Paoletti, F. and Gaetani, L. and Oeckl, P. and Steinacker, P. and others},
title = {{CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease}},
journal = {Neurology},
year = {2023},
doi = {10.1212/wnl.0000000000207371},
pmid = {37188538},
url = {https://doi.org/10.1212/wnl.0000000000207371}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results CSF β-synuclein, α-synuclein, SNAP-25, neurogranin, and NfL levels did not differ between LBD (n = 101, age 67.2 ± 7.8 years, 27.7% females) and controls (age 64.8 ± 8.6 years, 39.3% females) and were increased in AD (AD-MCI: n = 30, AD-dem: n = 30, age 72.3 ± 6.0 years, 63.3% females) compared with both groups ( p < 0.001 for all comparisons).
- CSF α-synuclein was significantly decreased only in patients with LBD with T- profiles compared with controls ( p = 0.0448).
- Discussion LBD/A+T+ and AD cases showed significantly increased CSF levels of synaptic and neuroaxonal biomarkers compared with LBD/A-T- and control subjects.
Why it matters
In patients with Lewy body disease, several CSF synaptic and neuroaxonal markers did not differ from controls but were increased in Alzheimer's disease, and one marker was decreased only in a specific subgroup. This is about using CSF markers to detect co-occurring Alzheimer's pathology in Lewy body disease, not about treating, curing or preventing it.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants101
- Effect size27.7%; 39.3%; 63.3%
- Evidence strengthLow
How this study scored 54/100
Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 101 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 39 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.8 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 3 / 6 | Cited 6.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 2 / 4 | Cited 33 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Markus Otto: h-index 95 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Perugia: institution h-index 747 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37188538) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1212/wnl.0000000000207371
- PubMed: 37188538
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.